Cargando…

非小细胞肺癌中驱动基因状态与免疫治疗相关性的研究进展

In recent years, the checkpoint inhibitors targeted programmed cell death 1 (PD-1) and its ligand 1 (PD-1 ligand, PD-L1) achieved landmark significance in treating a variety of cancers including non-small cell lung cancer (NSCLC). However, current immunotherapy is not precise enough, only 15%-20% of...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500499/
https://www.ncbi.nlm.nih.gov/pubmed/31014442
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.06
_version_ 1783415957956329472
collection PubMed
description In recent years, the checkpoint inhibitors targeted programmed cell death 1 (PD-1) and its ligand 1 (PD-1 ligand, PD-L1) achieved landmark significance in treating a variety of cancers including non-small cell lung cancer (NSCLC). However, current immunotherapy is not precise enough, only 15%-20% of the unselected patients can benefit from the therapy, and there is a possibility of hyperprogression (HP). Therefore, how to select the dominant population is crucial. Although many studies have emphasized the importance of PD-L1 and tumor mutation burden (TMB) and other indicators to guide immunotherapy, current PD-L1 expression level and mutation load cannot be used as a decisive and excluded predictive marker based on various obstacles. With the deepening of research, we found that there is a close relationship between lung cancer-driver gene mutation and aberrant activation of PD-1/PD-L1 signal pathways, and the correlation between gene mutation and immunotherapy efficacy has broad research value. This article will revolve around the above issues.
format Online
Article
Text
id pubmed-6500499
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-65004992019-05-21 非小细胞肺癌中驱动基因状态与免疫治疗相关性的研究进展 Zhongguo Fei Ai Za Zhi 综述 In recent years, the checkpoint inhibitors targeted programmed cell death 1 (PD-1) and its ligand 1 (PD-1 ligand, PD-L1) achieved landmark significance in treating a variety of cancers including non-small cell lung cancer (NSCLC). However, current immunotherapy is not precise enough, only 15%-20% of the unselected patients can benefit from the therapy, and there is a possibility of hyperprogression (HP). Therefore, how to select the dominant population is crucial. Although many studies have emphasized the importance of PD-L1 and tumor mutation burden (TMB) and other indicators to guide immunotherapy, current PD-L1 expression level and mutation load cannot be used as a decisive and excluded predictive marker based on various obstacles. With the deepening of research, we found that there is a close relationship between lung cancer-driver gene mutation and aberrant activation of PD-1/PD-L1 signal pathways, and the correlation between gene mutation and immunotherapy efficacy has broad research value. This article will revolve around the above issues. 中国肺癌杂志编辑部 2019-04-20 /pmc/articles/PMC6500499/ /pubmed/31014442 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.06 Text en 版权所有©《中国肺癌杂志》编辑部2019 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 综述
非小细胞肺癌中驱动基因状态与免疫治疗相关性的研究进展
title 非小细胞肺癌中驱动基因状态与免疫治疗相关性的研究进展
title_full 非小细胞肺癌中驱动基因状态与免疫治疗相关性的研究进展
title_fullStr 非小细胞肺癌中驱动基因状态与免疫治疗相关性的研究进展
title_full_unstemmed 非小细胞肺癌中驱动基因状态与免疫治疗相关性的研究进展
title_short 非小细胞肺癌中驱动基因状态与免疫治疗相关性的研究进展
title_sort 非小细胞肺癌中驱动基因状态与免疫治疗相关性的研究进展
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500499/
https://www.ncbi.nlm.nih.gov/pubmed/31014442
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.06
work_keys_str_mv AT fēixiǎoxìbāofèiáizhōngqūdòngjīyīnzhuàngtàiyǔmiǎnyìzhìliáoxiāngguānxìngdeyánjiūjìnzhǎn
AT fēixiǎoxìbāofèiáizhōngqūdòngjīyīnzhuàngtàiyǔmiǎnyìzhìliáoxiāngguānxìngdeyánjiūjìnzhǎn
AT fēixiǎoxìbāofèiáizhōngqūdòngjīyīnzhuàngtàiyǔmiǎnyìzhìliáoxiāngguānxìngdeyánjiūjìnzhǎn